AFCR shared on LinkedIn:
“What does it take to turn a scientific breakthrough into something that can truly change a patient’s life? That question shaped many of the conversations on Day One of BIOHK 2026 in Hong Kong.
Dr. Sujuan Ba, President, CEO, and Founder of the Asian Fund for Cancer Research Limited (AFCR), represented AFCR at BIOHK 2026 as one of the supporting organizations actively promoting innovations to benefit patients in Hong Kong and globally.
One of the day’s most compelling cancer-focused presentations came from Prof. Yuk-Ming Dennis Lo, Vice-Chancellor and President of The Chinese University of Hong Kong, who discussed advances in cell-free DNA and fragmentomics that are helping researchers explore more informative, minimally invasive approaches to earlier cancer detection.
- But discovery is only part of the journey. How do we make sure innovation is safe, trustworthy, and accessible?
- How do we build the clinical, regulatory, and collaborative pathways needed to move promising science toward patients?
Hong Kong’s ability to connect the Greater Bay Area with international research, capital, clinical development, and regulatory expertise can help strengthen that pathway.”
